Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Proteasome subunit beta type is a class of proteins that constitute the beta subunits of the 20S core proteasome complex, a large, multisubunit protease responsible for the ATP/ubiquitin-dependent degradation of intracellular proteins. The 20S core is a barrel-shaped assembly composed of four rings: two outer alpha rings and two inner beta rings, each containing seven subunits. Of the beta subunits, types 1, 2, and 5 (e.g., PSMB1, PSMB2, PSMB5) contain proteolytically active sites that confer different cleavage specificities (caspase-like, trypsin-like, chymotrypsin-like activities). These subunits are essential for regulated protein degradation, controlling cell cycle, apoptosis, and immune responses. Dysfunction or altered expression of these subunits is implicated in various disease processes, and selective inhibition of proteasome beta subunits (particularly beta type-5) has led to the development of clinically approved anti-cancer drugs.
Inhibition of proteasome activity (typically targeting the chymotrypsin-like activity of the beta type-5 subunit), leading to accumulation of ubiquitinated proteins, cell cycle arrest, and apoptosis
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Proteasome subunit beta type (PSMB).